Department of Oral Pathology and Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan.
Center for Comprehensive Genomic Medicine, Okayama University Hospital, Okayama, Japan.
JCI Insight. 2022 Jan 11;7(1):e148960. doi: 10.1172/jci.insight.148960.
Accumulating evidence has shown that cancer stroma and BM-derived cells (BMDCs) in the tumor microenvironment (TME) play vital roles in tumor progression. However, the mechanism by which oral cancer stroma recruits any particular subset of BMDCs remains largely unknown. Here, we sought to identify the subset of BMDCs that is recruited by cancer stroma. We established a sequential transplantation model in BALB/c nude mice, including (a) BM transplantation of GFP-expressing cells and (b) coxenografting of patient-derived stroma (PDS; 2 cases, designated PDS1 and PDS2) with oral cancer cells (HSC-2). As controls, xenografting was performed with HSC-2 alone or in combination with normal human dermal fibroblasts (HDF). PDS1, PDS2, and HDF all promoted BMDC migration in vitro and recruitment in vivo. Multicolor immunofluorescence revealed that the PDS coxenografts recruited Arginase-1+CD11b+GR1+GFP+ cells, which are myeloid-derived suppressor cells (MDSCs), to the TME, whereas the HDF coxenograft did not. Screening using microarrays revealed that PDS1 and PDS2 expressed CCL2 mRNA (encoding C-C motif chemokine ligand 2) at higher levels than did HDF. Indeed, PDS xenografts contained significantly higher proportions of CCL2+ stromal cells and CCR2+Arginase-1+CD11b+GR1+ MDSCs (as receiver cells) than the HDF coxenograft. Consistently, a CCL2 synthesis inhibitor and a CCR2 antagonist significantly inhibited the PDS-driven migration of BM cells in vitro. Furthermore, i.p. injection of the CCR2 antagonist to the PDS xenograft models significantly reduced the CCR2+Arginase-1+CD11b+GR1+ MDSC infiltration to the TME. In conclusion, oral cancer stroma-secreted CCL2 is a key signal for recruiting CCR2+ MDSCs from BM to the TME.
越来越多的证据表明,肿瘤微环境(TME)中的癌症基质和骨髓来源的细胞(BMDC)在肿瘤进展中起着至关重要的作用。然而,口腔癌基质招募任何特定亚群的 BMDC 的机制在很大程度上仍然未知。在这里,我们试图确定被癌症基质招募的 BMDC 亚群。我们在 BALB/c 裸鼠中建立了一个序贯移植模型,包括(a)GFP 表达细胞的 BM 移植和(b)患者来源的基质(PDS;2 例,分别命名为 PDS1 和 PDS2)与口腔癌细胞(HSC-2)的共移植。作为对照,单独或与正常人真皮成纤维细胞(HDF)共移植 HSC-2。PDS1、PDS2 和 HDF 均在体外促进 BMDC 迁移和体内募集。多色免疫荧光显示,PDS 共移植招募了 Arg1+CD11b+GR1+GFP+细胞,即髓系来源的抑制细胞(MDSC)到 TME,而 HDF 共移植则没有。使用微阵列进行筛选显示,PDS1 和 PDS2 表达 CCL2 mRNA(编码 C-C 基序趋化因子配体 2)的水平高于 HDF。事实上,PDS 移植瘤含有明显更高比例的 CCL2+基质细胞和 CCR2+Arg1+CD11b+GR1+MDSC(作为接收细胞)比 HDF 共移植瘤。一致地,CCL2 合成抑制剂和 CCR2 拮抗剂显著抑制了 PDS 驱动的 BM 细胞在体外的迁移。此外,向 PDS 移植瘤模型腹腔注射 CCR2 拮抗剂显著减少了 TME 中 CCR2+Arg1+CD11b+GR1+MDSC 的浸润。总之,口腔癌基质分泌的 CCL2 是从 BM 招募 CCR2+MDSC 到 TME 的关键信号。